Lemtrada Patients Have May Have Safer Options

Lemtrada Stroke Lawsuit News

Lemtrada often does damage to the lining of the arteries that encourages potentially deadly blood clots

Tuesday, December 8, 2020 - An article published in Multiple Sclerosis News Today speaks to patients with advanced relapse remitting multiple sclerosis (RRMS), asking for their input on a new and untested form of disease-modifying therapy (DMT). The authors compare Lemtrada to the new Stem Cell Therapy that could be made available in 2021 and will require the patient to make some decisions. Stem cell therapy is more than twice as effective as Lemtrada in preventing the symptoms of RRMS. According to Multiple Sclerosis News, "no evidence of disease activity (NEDA) was achieved by more than twice as many AHSCT-treated patients than by those given Lemtrada (88% vs. 37%) at three years, results showed." Compared with Lemtrada, AHSCT was also associated with a significantly lower annualized relapse rate (0.04 vs. 0.1 in the Lemtrada group), and a significantly greater proportion of patients free from MRI events (93% vs. 55%), relapses (93% vs. 70%), or confirmed disability progression (97% vs. 82%).

RRMS patients need to be aware that stem cell therapy carries life-threatening side effects. Lemtrada, it is said, is like stem cell therapy in that the drug first destroys a patient's immune system to a degree in the hope that it will rebuild stronger, according to MSNT. Patients hoping to try stem cell therapy will first have to be relatively healthy before having their immune systems ablated before given the modified stem cells. Lemtrada stroke lawsuits are handled by top national attorneys with vast experience and a winning track record litigating against big pharmaceutical companies and offer a free no obligation consultation before filing a claim.

A patient risks developing the sometimes deadly graft versus host disease if their body rejects the transfusion. Stem Cell Transplants can be more complicated than sitting down for Lemtrada infusions. Stem cells are harvested from the patient's bone marrow located in the large hip bones. A single needle is inserted to withdraw the bone marrow. The cylinder is replaced with a new syringe inserted to extract more bone marrow. Only a single needle injection is required, and the doctor makes many insertions into the bone marrow. A patient is at risk during the first few months after their first stem cell injection when their immune system is weakest. Lemtrada, on the other hand, shocks the immune system to such an extent that a patient risks the same complications as anyone with a weakened immune system, but also carries the risk of sudden death from having a heart attack or stroke. Lemtrada's toxicity attacks the lining of the arteries which are normally smooth and allowing blood to flow freely. When Lemrada erodes that lining, blood clots can develop and cause a heart attack if they travel to the heart and a stroke if they travel to the brain. Either treatment is only to be attempted as a last resort when all other options have been exhausted. MSN tells its readers that the risks are greater with stem cell therapy during the first three months whereas Lemtrada's risks as great during this time and far greater thereafter.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.